secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001171843-26-002799
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign
--------------------------------------------------------------------------------

- Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.
- Gross margin 64.2% vs 56.1% YoY on operational execution and favorable mix.
- GAAP loss from continuing ops $5.1M ($0.37 diluted); adjusted net income $3.8M ($0.27 diluted).
- Adjusted EBITDA $4.3M vs $0.1M prior year; FY2026 guidance reaffirmed (revenue $114-122.5M).
- Board members Jellison and Larsen resign effective 2026 annual meeting; share repurchase $15M completed at avg $10.76/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/0001171843-26-002799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184326002799/f8k_042926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer